Phase 1 Brain Cancer Trial, Recruiting NCT06199479 Sponsor: M.D. Anderson Cancer Center Condition: Brain Cancer
Back to Brain Cancer

Phase 1 Brain Cancer Trial, Recruiting

NCT06199479
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are over 18 years of age
  • People who are willing to take part in the study and attend all required appointments and assessments
  • People who have previously been treated for a brain tumor, have a new suspicious finding on a brain scan, and are being considered for a biopsy to investigate it
  • People who are willing to have the required brain imaging done within 14 days before their planned procedure (and ideally within 3 days)

Who may not be able to join:

  • People whose kidneys are not working well enough — specifically, those with a kidney filtration rate (a measure of kidney function) below 30 for MRI contrast dye, or below 45 for CT contrast dye. People with a kidney filtration rate between 30 and 45 may still be able to have a CT scan without contrast dye (confirm with trial site)
  • People who have certain metal implants or electronic devices in their body that are not safe for MRI scanning — this includes things like pacemakers, defibrillators, cochlear implants, insulin pumps, nerve stimulators, metal fragments in the eye, certain surgical clips in the brain or body, and some heart valves, among others. However, people with certain devices that have manufacturer-approved MRI scanning guidelines may still be eligible to participate (confirm with trial site)
  • People who are pregnant, or who have severe claustrophobia that does not respond to oral medication
  • People who have a known allergy to iodine-based or gadolinium-based contrast dyes used in imaging. If only one type of dye is a problem, imaging using the other type may still be possible (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dawid Schellingerhout, MD, M.D. Anderson Cancer Center

Phone: (713) 794-5673

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
4 June 2024
Est. completion
31 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Safety and adverse events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov